Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 16, 2026, ANDA 205171 (Almotriptan Malate), held by Mylan, was first approved by FDA on Nov 9, 2015, with 1 approved supplement and 0 published complete response letters.
First approved: Nov 9, 2015
Review: Standard
Supplements approved: 1
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Almotriptan tablets are a 5HT 1B/1D receptor agonist (triptan) indicated for:
Acute treatment of migraine attacks in adults with a history of migraine with or without aura
Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more Important Limitations:
Use only after a clear diagnosis of migraine has been established
In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms was not established
Not intended for the prophylactic therapy of migraine
Not indicated for the treatment of cluster headache 1.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters